59
Adakveo (Crizanlizumab): Revolutionizing Sickle Cell Crisis Management or Overhyped?
Adakveo (crizanlizumab), recently approved for reducing vaso-occlusive crises (VOCs) in sickle cell patients 16+, is gaining traction. Unlike traditional analgesics, it targets VOCs at the s…
10 comments
258 views